Current approach to malignant mesothelioma of the pleura.
Malignant mesothelioma of the pleura occurs primarily in individuals who were exposed to asbestos either in the workplace or home. The incidence of malignant mesothelioma is rising and, reflective of the malignancy's long latency period, is expected to continue to increase into the next century. Current treatment measures, including surgery, radiation therapy, chemotherapy, intrapleural therapy, and combined-modality therapies, have had varying impacts on survival. This paper explores current trends in the treatment of malignant pleural mesothelioma.
Aisner
J
J
Department of Medicine, University of Medicine and Dentistry of New Jersey, Robert-Wood Johnson Medical School, Cancer Institute of New Jersey, New Brunswick, USA.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001194:Asbestos / Q000009:adverse effects; D003131:Combined Modality Therapy; D006801:Humans; D008654:Mesothelioma / Q000209:etiology / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D009367:Neoplasm Staging; D010994:Pleura / Q000601:surgery; D010997:Pleural Neoplasms / Q000209:etiology / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D011013:Pneumonectomy
D000970:Antineoplastic Agents; D001194:Asbestos